Navigation Links
Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer
Date:2/1/2008

Dr. Pollard Brings the Highest Level of Clinical Immunology Expertise

MCLEAN, Va. and BUDAPEST, Hungary, Feb. 1 /PRNewswire/ -- Genetic Immunity(R), a US/Hungarian clinical-stage biopharmaceutical company focused on the development and commercialization of its patented immunotherapeutic platform technology, announced that it has appointed Richard B. Pollard, M.D. as Chief Medical Officer.

Dr. Pollard has been a leader in HIV/AIDS research for more than twenty years; he cared for his first patient with AIDS in 1982, and continues to provide primary care for hundreds of patients with HIV and related conditions. Dr. Pollard has been involved in the development of new treatments for the HIV, herpes, and hepatitis viruses. His laboratory, one of the five immunology specialty laboratories supported by the AIDS Clinical Trials Group (ACTG), performs multiple assays to monitor immunologic changes to HIV and opportunistic viral pathogens.

In addition, Dr. Pollard is Professor of Internal Medicine and Microbiology and Chief of the Division of Infectious Diseases at the University of California, Davis Medical School in Sacramento, CA. He currently serves as the Principal Investigator of the Immunology Specialty Laboratory, Chair of the ACTG Laboratory Evaluation Subcommittee, and Principal Investigator of the California Research Center for the Biology of HIV in Minorities.

Dr. Pollard said, "I'm excited to join Genetic Immunity's scientifically strong team; I believe that this team has the depth to develop scalable in vivo immunotherapies from the research stage though clinical development in a number of indications. As someone who has spent a quarter century active in AIDS care, I'm excited to work on the DermaVir Patch product as it is one of the most innovative approaches to HIV treatment. As a researcher, I'm impressed that an exceptional clinical observation inspired a new immune therapy technology."

Julianna Lisziewicz, Ph.D., Co-Founder and CEO of Genetic Immunity, said, "We are delighted that Dr. Pollard has decided to join the Genetic Immunity team following on 10 years of collaboration. Dr. Pollard was a pioneer in the field of AIDS research and today is one of the key opinion-leaders in HIV/AIDS and infectious diseases. His position on our management team demonstrates his belief in the potential of our technology. His presence in Hungary brings the highest level of clinical immunology expertise to the country's emerging biopharmaceutical industry. Dr. Pollard's experience in clinical development makes him an ideal fit for our company and adds strength to what is already a robust team."

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian development stage company establishing leadership in next-generation biopharmaceuticals. The Company is leveraging its proprietary platform technology to create new markets for infectious diseases, cancer and allergy through the discovery, development and commercialization of topically administered immune therapies. These indications represent significant unmet medical need and potential for alternative treatment approaches. Genetic Immunity's lead product, the DermaVir Patch for the treatment of HIV/AIDS, was discovered by the Company's founders, and is in Phase II clinical development with the opportunity to be the first immune therapy approved for HIV-infected individuals.

About DermaVir Patch

The proprietary DermaVir Patch is a topically administered HIV immune therapy, which emerged from the clinical observations of Genetic Immunity's founders. Their examination of the "Berlin Patient" proved that induction of immune control of HIV replication is feasible in an infected patient. The Company has developed the DermaVir Patch to induce the immune system to kill HIV infected cells specifically and to make immune therapy accessible for the majority of HIV infected individuals, including children. The DermaVir Patch, currently in Phase II clinical trials, is comprised of two patented components: NanoComp and DermaPrep. NanoComp is an antigen composition platform that combines a disease-specific plasmid DNA with the Company's formulation technology. The unique DNA for the DermaVir Patch product encodes the majority of HIV antigens, allowing a broad immune response. DermaPrep is a topical administration device by which NanoComp is delivered specifically into the dendritic cells.

Contacts:

The Ruth Group

Investors

Sara Ephraim

+1-646-536-7002

sephraim@theruthgroup.com

Media

Janine McCargo

+1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
2. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
3. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
4. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
5. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
6. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
7. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
8. deCODE genetics Announces Third Quarter 2007 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
10. ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results
11. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):